journal article·2021-08-11

Surface Decoration via Physical Interaction of Cupric Diethyldithiocarbamate Nanocrystals and Its Impact on Biodistribution and Tumor Targeting

Zhengjie Meng, Hao Wang, Xue Fang, Zhangya Liu, Zheng Yang, Jiahui Yong, Qingqing Yang, Yunhao Bai, Hao Ren, Hao Xu, Xueming Li

ACS Applied Materials & Interfaces· Volume 13· Issue 31
Publisher page

Abstract

The vascular wall is the first physiologic barrier that circulating nanoparticles (NPs) encounter, which also is a key biological barrier to cancer drug delivery. NPs can continually scavenge the endothelium for biomarkers of cancer, and the chance of NPs' extravasation into the tumors can be enhanced. Here, we envision P-selectin as a target for specific delivery of drug nanocrystals to tumors. The cupric diethyldithiocarbamate nanocrystals (CuET NCs) were first prepared by an antisolvent method, and then nanocrystals were coated with fucoidan via physical interaction. The fucoidan-coated CuET nanocrystals (CuET@Fuc) possess high drug loading and have the ability to interact with human umbilical vein endothelial cells expressing P-selectin, which transiently enhances the endothelial permeability and facilitates CuET@Fuc extravasation from the peritumoral vascular to achieve higher tumor accumulation of drugs than bare CuET NCs. The CuET NC shows poorer anticancer efficacy than CuET@Fuc at the same dose of CuET. Upon repeated dosing of CuET@Fuc for 2 weeks, no mortality was observed in treated melanoma-bearing mice, while the mortality in the control group and excipient-treated groups reached 23%. The growth rate of melanoma in the CuET@Fuc-treated group was significantly lower than those in other groups. Furthermore, an acute toxicity study revealed that CuET@Fuc is a safe formulation for cancer treatment.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Protease and Inhibitor Mechanisms

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

College of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University, Nanjing 211816, China

College of Pharmacy, Nanjing Tech University, Nanjing 211816, China

Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China

Funding

National Natural Science Foundation of China · Youth Foundation of Jiangsu Province

References (53)

Show source-provided references
1. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/disulfiram.
2. 10.1016/j.nano.2016.08.00110.1016/j.nano.2016.08.001 ↗
3. 10.1038/bjc.2013.53410.1038/bjc.2013.534 ↗
4. 10.1038/nature2501610.1038/nature25016 ↗
5. 10.1039/c5tx00210a10.1039/c5tx00210a ↗
6. 10.1016/j.jconrel.2013.06.03910.1016/j.jconrel.2013.06.039 ↗
7. 10.1016/j.jconrel.2016.07.01510.1016/j.jconrel.2016.07.015 ↗
8. 10.1038/533304a10.1038/533304a ↗
9. 10.1016/j.biomaterials.2020.11990210.1016/j.biomaterials.2020.119902 ↗
10. 10.1038/s41563-019-0566-210.1038/s41563-019-0566-2 ↗
11. 10.1016/j.apsb.2015.11.00510.1016/j.apsb.2015.11.005 ↗
12. 10.1038/s41563-020-0755-z10.1038/s41563-020-0755-z ↗
13. 10.1038/s41565-020-0759-510.1038/s41565-020-0759-5 ↗
14. 10.1016/j.addr.2020.06.01310.1016/j.addr.2020.06.013 ↗
15. 10.1016/j.addr.2016.09.00610.1016/j.addr.2016.09.006 ↗
16. 10.1016/j.jconrel.2011.06.00110.1016/j.jconrel.2011.06.001 ↗
17. 10.1182/blood-2004-07-269810.1182/blood-2004-07-2698 ↗
18. 10.1165/ajrcmb.12.3.753297910.1165/ajrcmb.12.3.7532979 ↗
19. 10.1126/scitranslmed.aaf737410.1126/scitranslmed.aaf7374 ↗
20. 10.1016/j.semcancer.2010.04.00510.1016/j.semcancer.2010.04.005 ↗
21. 10.1007/s12307-010-0043-610.1007/s12307-010-0043-6 ↗
22. 10.1517/14728222.11.11.147310.1517/14728222.11.11.1473 ↗
23. 10.1002/smll.20180360110.1002/smll.201803601 ↗
24. 10.1007/s10350-007-9065-710.1007/s10350-007-9065-7 ↗
25. 10.1016/j.canlet.2020.11.02110.1016/j.canlet.2020.11.021 ↗
26. 10.1016/j.ijrobp.2016.10.03710.1016/j.ijrobp.2016.10.037 ↗
27. 10.1007/s10439-008-9444-910.1007/s10439-008-9444-9 ↗
28. 10.1016/j.surg.2011.09.04510.1016/j.surg.2011.09.045 ↗
29. 10.1002/ijc.100910.1002/ijc.1009 ↗
30. 10.2967/jnumed.110.08585210.2967/jnumed.110.085852 ↗
31. 10.1016/j.biomaterials.2017.11.04710.1016/j.biomaterials.2017.11.047 ↗
32. 10.1021/mp200154k10.1021/mp200154k ↗
33. 10.18632/oncotarget.2389810.18632/oncotarget.23898 ↗
34. 10.3390/md1612051010.3390/md16120510 ↗
35. 10.1002/jbm.a.3652610.1002/jbm.a.36526 ↗
36. 10.1016/j.jconrel.2016.12.04010.1016/j.jconrel.2016.12.040 ↗
37. 10.1016/j.chemosphere.2012.07.02910.1016/j.chemosphere.2012.07.029 ↗
38. 10.1016/j.jconrel.2016.09.03110.1016/j.jconrel.2016.09.031 ↗
39. 10.1371/journal.pone.015341610.1371/journal.pone.0153416 ↗
40. 10.1016/j.jconrel.2017.08.03110.1016/j.jconrel.2017.08.031 ↗
41. 10.1021/jacs.9b0350310.1021/jacs.9b03503 ↗
42. 10.1016/S1003-6326(06)60085-X10.1016/S1003-6326(06)60085-X ↗
43. 10.1016/j.carbpol.2018.03.08010.1016/j.carbpol.2018.03.080 ↗
44. 10.1038/srep4642410.1038/srep46424 ↗
45. 10.1038/s41467-020-20359-x10.1038/s41467-020-20359-x ↗
46. 10.1021/acs.nanolett.8b0520210.1021/acs.nanolett.8b05202 ↗
47. 10.1038/sj.onc.120966410.1038/sj.onc.1209664 ↗
48. 10.1152/ajpheart.00491.201010.1152/ajpheart.00491.2010 ↗
49. 10.1016/j.biopsych.2012.05.00410.1016/j.biopsych.2012.05.004 ↗
50. 10.1021/ja208433810.1021/ja2084338 ↗
51. 10.1021/acsnano.7b0673410.1021/acsnano.7b06734 ↗
52. 10.3109/1061186980899683410.3109/10611869808996834 ↗
53. 10.1007/s40820-020-0384-810.1007/s40820-020-0384-8 ↗